News

News Subscription

Sep 06. 2024 / Ad hoc announcement
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea
Read more
Download
Aug 27. 2024 / Ad hoc announcement
European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea
Read more
Download
Aug 21. 2024
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Read more
Download
Aug 13. 2024 / Ad hoc announcement
Basilea reports strong 2024 half-year results and significantly increases full-year revenue and profit guidance
Read more
Download
Jun 20. 2024
Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
Read more
Download
May 16. 2024
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Read more
Download
May 03. 2024
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
Read more
Download
Apr 24. 2024
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
Read more
Download
Apr 09. 2024
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
Read more
Download
Apr 04. 2024 / Ad hoc announcement
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications
Read more
Download